Skip to main content
TipRanks
Go Ultimate75% OFF

4basebio UK Societas (88Q) AI Stock Analysis

0 Followers
DE:88Q

4basebio UK Societas

(XETRA:88Q)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Synthetic DNA positioningThe company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.
Negative Factors
Persistent and widening lossesThe combination of declining 2025 revenue and materially wider losses shows that the business has not yet converted its technology and revenue base into sustainable profitability. Negative operating and net margins leave limited internal funding capacity and make earnings improvement dependent on renewed growth or cost control.

4basebio UK Societas (88Q) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%DE:88Q-27.33%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 81.30M
Dividend Yield
―
Average Volume (3M)
409
Price to Earnings (P/E)
-4.5
Beta (1Y)
0.23
Revenue Growth
-57.54%
EPS Growth
-12.93%
Country
Germany
Employees
140
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

4basebio UK Societas Business Overview & Revenue Model

Company Description

4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutio...

4basebio UK Societas Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:88Q against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 102.93M13.5967.81%7.61%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:APTAGB:APTA46NeutralGBP 13.01M-12.17-46.61%―28.35%57.14%
GB:AVCTGB:AVCT40UnderperformGBP 299.86M-6.47-1293.07%―――
GB:FABGB:FAB40UnderperformGBP 5.32M-4.29-97.87%―7.38%44.13%
GB:OBDGB:OBD40UnderperformGBP 16.13M-0.29-451.74%―33.37%86.41%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:88QGB:AVCTGB:BVXPGB:OBDGB:FABGB:APTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:88Q and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:88Q4basebio UK Societas5.85-2.20-27.33%
GB:AVCTAvacta Group plc59.00-22.00-27.16%
GB:BVXPBioventix plc1970.00-17.97-0.90%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:FABFusion Antibodies Plc4.25-8.00-65.31%
GB:APTAAptamer Group Plc0.36-0.57-60.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.